Literature DB >> 28861185

Primary Ovarian Clear Cell Adenofibroma of Borderline Malignancy.

Ebru Cakir1, Engin Aydin1, Nılufer Imamoglu Durmus1, Emine Samdanci1, Nurhan Sahin1, Zeynep Nurkabul1.   

Abstract

Clear cell adenofibromas of borderline malignancy are extremely rare tumors of ovary. We report a case of ovarian borderline clear cell adenofibroma in a 53-year-old postmenopausal woman. The patient had abdominal hysterectomy and bilateral salpingo-oophorectomy because of left adnexeal mass. The tumor was well-demarcated, solid and multinodular mass, measuring 12×10.5×6 cm. Microscopically, the tumor consisted mainly of fibrous stroma and glands composed of cells with eosinophilic or clear cytoplasm. The epithelium focally showed moderate nuclear atypia and mitotic figures. The histopathologic diagnosis was borderline clear cell adenofibroma. The patient is alive and well without signs of recurrence 6 months after the operation.

Entities:  

Year:  2012        PMID: 28861185      PMCID: PMC5563913          DOI: 10.5001/omj.2012.20

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  7 in total

1.  Borderline clear cell adenofibroma with extensive hemorrhagic necrosis.

Authors:  Jing-Lan Liu; Pei-Yi Chu; Kun-Tu Yeh; Ren-Hung Huang
Journal:  Hematol Oncol Stem Cell Ther       Date:  2010

2.  A pregnant woman with clear cell adenocarcinoma of the ovary arising from endometriosis and with benign and borderline adenofibroma of the clear cell and endometrioid types.

Authors:  T Sugiyama; T Nishida; A Kataoka; N Okura; S Iwanaga; M Yakushiji
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1997-03       Impact factor: 2.435

3.  Benign and borderline clear cell adenofibromas of the ovary.

Authors:  D A Bell; R E Scully
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

4.  Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tomoyuki Yoshikawa; Kazuya Kudoh; Tsunekazu Kita; Kenichi Furuya; Seiichi Tamai; Osamu Matsubara
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

5.  Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Authors:  Emanuela Veras; Tsui-Lien Mao; Ayse Ayhan; Stefanie Ueda; Hong Lai; Mutlu Hayran; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

6.  Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.

Authors:  S Yamamoto; H Tsuda; M Takano; K Hase; S Tamai; O Matsubara
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

7.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

  7 in total
  3 in total

1.  Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management.

Authors:  Giulio Ricotta; Amandine Maulard; Massimo Candiani; Catherine Genestie; Patricia Pautier; Alexandra Leary; Cyrus Chargari; Giorgia Mangili; Philippe Morice; Sébastien Gouy
Journal:  Ann Surg Oncol       Date:  2021-10-01       Impact factor: 5.344

2.  Endometriosis after surgical menopause mimicking pelvic malignancy: surgeons' predicament.

Authors:  Rani A Bhat; Melissa Teo; Akhil Krishnanand Bhat
Journal:  Oman Med J       Date:  2014-05

3.  Borderline Clear Cell Adenofibroma of the Ovary.

Authors:  Pilaiwan Kleebkaow; Apiwat Aue-Aungkul; Amornrat Temtanakitpaisan; Chumnan Kietpeerakool
Journal:  Case Rep Pathol       Date:  2017-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.